

Rakovina Therapeutics Inc. Receives Notice of Allowance for New U.S. Patent Covering kt-2000 series PARP Inhibitors

Vancouver, British Columbia, October 7, 2021 /CNW/ -- Rakovina Therapeutics Inc. (the “Company”) (TSX-V: RKV) today announced that the Company has received notice of allowance from the United States Patent and Trademark Office (USPTO) for a patent entitled “Tricyclic Inhibitors of Poly(ADP-Ribose) Polymerase.”

The granted patent claims cover the composition of matter and uses of drug candidates from Rakovina Therapeutics’ kt-2000 series, one of three novel series of DNA-damage response (DDR) inhibitors being researched by the Company as potential targeted cancer therapies under a collaborative research agreement with the University of British Columbia.

“This US patent is an important component of our strategy to establish a global intellectual property portfolio around our novel DNA-damage response inhibitor technologies,” said Prof. Mads Daugaard, Rakovina Therapeutics’ president and chief scientific officer.

About Rakovina’s kt-2000 Series Drug Candidates

Rakovina Therapeutics’ kt-2000 series drug candidates are oral, targeted small-molecule inhibitors of poly (ADP-ribose) polymerase (PARP). PARP inhibitors have become integral in the treatment of cancers harboring deficiencies in homologous DNA repair (HR) leading to improved clinical outcomes in subsets of ovarian, breast and prostate cancer. Established data demonstrate that lead candidates from Rakovina Therapeutics’ kt-2000 series exhibit potency comparable to FDA-approved PARP-inhibitors and potent anti-cancer activity in preclinical animal models. Rakovina Therapeutics’ kt-2000 series lead candidates are being optimized around potential differentiating factors and competitive advantages, including the ability to cross the blood brain barrier in order to treat tumors that have metastasized to or originate in the brain.

About Rakovina Therapeutics Inc.

Rakovina Therapeutics Inc. was established in 2020 to develop new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies. Further information may be found at www.rakovinatherapeutics.com.

Additional Information

The TSXV has in no way passed upon the merits of the Qualifying Transaction and has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Notice regarding forward-looking statements:

This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the

Company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company’s most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company’s profile page at www.sedar.com.

Contact:

Rakovina Therapeutics Inc.

David Hyman

Chief Financial Officer

Email: info@rakovinatherapeutics.com

Investor Relations Contact

IR@rakovinatherapeutics.com

Media Contact

MEDIA@rakovinatherapeutics.com